Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706367 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
A Phase 1 study of Clostridium Difficile Associated Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
- 4
- Study locations
NCT01706367: Completed Phase 1 study of Clostridium Difficile Associated Disease, sponsored by Pfizer.
NCT01706367 is a Phase 1 study of Clostridium Difficile Associated Disease that has completed, run by Pfizer. The registered enrollment target is 192 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01706367, a Phase 1 study of Clostridium Difficile Associated Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years. The main goal of the study is to determine how safe and well-tolerated the vaccine is. In addition, the study aims to assess the immune response to the C difficile vaccine.
Conditions Studied
Interventions
- BIOLOGICAL C. difficile vaccine
- BIOLOGICAL C. difficile vaccine +adjuvant
Study Locations (4)
Florida
- Pfizer Investigational Site - Pembroke Pines
- Pfizer Investigational Site - South Miami
Kansas
- Pfizer Investigational Site - Overland Park
North Carolina
- Pfizer Investigational Site - Cary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
What the finished NCT01706367 record still lists
NCT01706367 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher).
The record links to 1 condition, with Clostridium Difficile Associated Disease appearing as the primary indexed condition, and to 2 interventions - of which C. difficile vaccine is the first listed.
NCT01706367 reports a single indexed study location in Florida, Kansas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01706367 about?
NCT01706367 is a clinical study titled "Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years". This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years. The main goal of the study is to determine how safe and well-tolerated the vaccine is. In addition, the study ...
What is the current status of trial NCT01706367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2012-09. Estimated completion is 2014-01.
What conditions does trial NCT01706367 study?
This clinical trial studies the following conditions: Clostridium Difficile Associated Disease.
What interventions are being tested in trial NCT01706367?
The interventions under investigation include: C. difficile vaccine (BIOLOGICAL), C. difficile vaccine +adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01706367?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01706367 being conducted?
This trial has 4 study locations across Florida, Kansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Associated Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01706367's enrollment target sits among peer trials
192 282nd of 2000 higher than 1,718 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia